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Upregulation of Inflammatory Cytokines and
Oncogenic Signal Pathways Preceding Tumor
Formation in a Murine Model of T-Cell Lymphoma
in Skin
Xuesong Wu1, Ryan E. Sells1 and Sam T. Hwang1
The tumor microenvironment, including its inflammatory components, regulates tumor progression. Herein,
we explore the relationship between inflammation and the progression of T-cell lymphoma in the cutaneous
microenvironment. Injection of MBL2 murine T lymphoma cells into ear skin of C57BL/6 and immunodeficient
SCID/Beige mice resulted in tumor formation in only the latter group. However, induction of skin inflammation
by one topical application of DNFB following MBL2 inoculation in C57BL/6 mice resulted in progressive
high-grade lymphoma. The DNFB-regulated tumor formation was blocked by early, but not late, application
of a potent topical corticosteroid. At 2 days after implantation, a 10-fold decrease in MBL2 cell apoptosis
was detected in DNFB-treated ears compared with vehicle control. After DNFB treatment, Gr-1high neutrophils
and F4/80þ macrophages constituted the majority of tumor-infiltrating CD45þ leukocytes. Depletion
of macrophages by clodronate-containing liposomes blocked the tumor-promoting effect of DNFB.
Transcriptional profiling of inflammatory cytokines and chemokines after DNFB treatment revealed robust
changes in genes that are important in chemotaxis, proliferation, and apoptosis. Activation of oncogenic signal
pathways, including NF-kB, was also detected. This work provides insights into the cellular and molecular
pathways that mediate lymphoma progression and may have applicability to human cutaneous T-cell
lymphomas.
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INTRODUCTION
The cutaneous T-cell lymphomas (CTCLs) are a diverse group
of skin-localizing lymphomas of which mycosis fungoides
(MF) represents the majority of reported cases (Hwang et al.,
2008). Although most MF patients present with chronic skin-
limited patches and thin plaques, skin lesions may progress
to nodular ulcerating tumors and visceral metastasis. It has
been suggested that MF arises in a background of chronic
inflammation, perhaps as a response to chronic antigen
stimulation (Burg et al., 2001). Although some progress has
been made in the understanding of CTCL immune patho-
physiology, the molecular mechanisms of CTCL development
remain elusive (Hwang et al., 2008).
Mounting evidence indicates that an inflammatory envir-
onment contributes to tumor development (Grivennikov
et al., 2010). Tumor-associated macrophages, the most
frequently found immune cells within the tumor microenvir-
onment, promote tumor growth and correlate with poor
clinical prognosis in many common cancers (Qian and
Pollard, 2010). Tumor-associated macrophages produce
cytokines that activate oncogenic pathways, promoting the
survival, proliferation, and invasion of malignant cells.
Moreover, other cytokines associated with tumor-associated
macrophages alter the function of inflammatory cells in the
tumor environment, rendering them less capable of develop-
ing an effective antitumor response (Mantovani et al., 2008).
The cytokines present within the CTCL milieu are derived
from malignant T cells, bystander T cells, infiltrating inflam-
matory cells, as well as skin-resident cells (i.e., keratinocytes
or endothelial cells). IL-7, found to be elevated in both
plasma and skin lesions of CTCL patients, has been shown
to promote T-cell survival and proliferation within skin
lesions (Yamanaka et al., 2006b). IL-18, a pleiotropic pro-
inflammatory cytokine produced by the monocyte/macro-
phage lineage as well as keratinocytes, was also significantly
elevated in plasma and skin lesion in CTCL patients and
may contribute to the T helper cell type 2 bias in CTCLs
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(Yamanaka et al., 2006a). Other cytokines, including IL-1b,
IL-17, and IL-23, have also been reported to be expressed
in CTCLs (Tron et al., 1988; Ciree et al., 2004; Doherty et al.,
2006).
We have established a mouse model of T-cell lymphoma
progression in the skin that is triggered by an inflammatory
stimulus. In this model, transplanted murine T lymphoma
cells MBL2 (van Hall et al., 2000) fail to form tumors in the
ear skin of syngeneic mice but rapidly develop diffusely
thickened tumors following a single application of a contact
sensitizer. We examined the cellular immune mechanisms
underlying lymphoma development under these conditions
and characterized the early gene expression pathways that
preceded tumor development, yielding inflammatory path-
ways and targets that may be relevant for clinical intervention
in human CTCLs.
RESULTS
Transplanted tumors form in the ear skin of immunodeficient
but not in immunocompetent C57BL/6 mice following
injection of MBL2 cells. MBL2 is a Moloney MuLV-induced
T-cell lymphoma cell line derived from C57BL/6 mice (van
Hall et al., 2000). MBL2, as well as clonally identical cell
lines such as RMA and EL-4, possess viral as well as nonviral
epitopes that are recognized by cytolytic T cells that aid in
tumor rejection (van Hall et al., 2000). We injected MBL2
cells into the ear skin of mice in an attempt to generate a
lymphoma model that recapitulates tumor-stage human
CTCLs. Interestingly, no tumor formation was observed in
immunocompetent syngeneic C57BL/6 mice even when up
to 400,000 tumor cells were injected per mouse ear. When
the same number of MBL2 cells was injected into immuno-
deficient SCID/Beige ear skin, tumors reproducibly formed in
all mice within 3 weeks (Figure 1a). For quantitative tracking
of tumor cells, we generated luciferase-expressing MBL2 cells
(MBL2-Luc) (Supplementary Figure S1 online). Quantification
of luciferase activity after injection of MBL2-Luc into C57BL/
6 ear skin indicated that tumor cells persisted and even
proliferated in the first week. Thereafter, luciferase activity
decreased prominently, becoming undetectable after 21
days. In contrast, SCID/Beige mice showed increased
luciferase activity and ultimately formed tumors (Figure 1b).
Thus, MBL2 lymphoma cells were immunogenic and subject
to host antitumor responses following implantation in
immunocompetent mice.
DNFB promotes tumor progression in immunocompetent
C57BL/6 mice
Because MBL2 cells did not form tumors in ear skin
of C57BL/6 mice, we used DNFB to induce local inflam-
mation possibly affecting tumor development. In the early
days following tumor inoculation, ears treated with a
single topical application of DNFB exhibited inflamma-
tory changes, i.e., redness, swelling, and slightly increased
thickness. After 2 weeks, diffusely thickened ear tumors were
present. Histologically, dense dermal sheets of malignant
cells reminiscent of tumor-stage MF were observed with
various leukocytes present within tumor lesions (Figure 2a).
Of note, 12-O-tetradecanoylphorbol-13-acetate, a tumor-
promoting agent used in multistep skin carcinogenesis
models, had no tumor-promoting activity, suggesting speci-
ficity in the response to DNFB (Figure 2b). We did not
observe distant visceral metastases in inoculated animals,
although growth of MBL2 tumors was observed in up to 20%
of mice in regional draining cervical lymph nodes whether or
not they were treated with DNFB.
To determine if tumor formation was related to inflamma-
tory changes, we treated the inoculated DNFB-applied ear
skin with a potent topical corticosteroid (clobetasol propio-
nate cream, 0.05%; Fougera, Melville, NY). On the day of
DNFB application, clobetasol treatment was alone applied to
the ventral ear skin, opposite the application of DNFB to
avoid contamination. For the next 5 days, tumor-inoculated
ears were treated with clobetasol on both ear surfaces. At 2
weeks after tumor inoculation, the mice treated with
clobetasol in the early phase had dramatically reduced tumor
formation (Figure 2c). Mice that either did not receive
clobetasol treatment or were treated with clobetasol at a
later phase (i.e., from day 10 to day 14, the last 5 days in
tumor development course) formed large ear tumors (Figure
2c and Supplementary Figure S2 online). Because these
results might be explained if clobetasol had directly inhibited
MBL2 proliferation or enhanced apoptosis of these cells, we
exposed MBL2 cells in vitro to dexamethasone, a more
soluble corticosteroid. Neither cell death nor proliferation
was significantly affected by dexamethasone at up to
1,000 nM concentration (Supplementary Figure S7 online).
Thus, DNFB promoted MBL2 lymphoma progression in the
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Figure 1. MBL2 ear skin tumors form in immunodeficient but not
immunocompetent mice. (a) MBL2 cells were injected (4105 cells per ear)
into the ear skin of C57BL/6 or SCID/Beige mice (5 mice per group;
experiment was repeated 45 times). Inoculated ears were observed twice
weekly for 1 month. Representative pictures of C57BL/6 (left) and SCID/Beige
(right) mouse ears at 21 days after MBL2 cell inoculation are shown.
(b) Kinetics of MBL2 tumor growth in mouse ears. At different time points
(three mice per time point), the ears were processed to determine the
luciferase level (arbitrary relative light unit (RLU)).
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ear skin via induction of corticosteroid-responsive inflamma-
tory responses.
An inflammatory environment blocks apoptosis and later
promotes proliferation of implanted MBL2 cells
To determine if early induction of inflammation is critical to
tumor formation, we examined early events, such as
apoptosis and proliferation of tumor cells, at 2 days after
implantation and treatment of ear skin with DNFB before
overt tumor formation was found. Before implantation,
MBL2 cells were labeled in vitro with CellTracker CMRA
(Invitrogen, Carlsbad, CA; Figure 3a, A) in order to identify
those cells within single-cell suspensions prepared from
whole ears (Figure 3a, B). After mouse ears were harvested
and prepared as single-cell suspensions, cells were analyzed
for apoptosis and necrosis by flow cytometry. In both DNFB-
and vehicle-treated ears, 33–36% of dead or late-phase
apoptosis cells (Annexin Vþ /7-AADþ ) were observed
among CMRA-labeled MBL2 tumor cells. However, the
percentage of apoptotic cells (Annexin Vþ /7-AAD–) was
much lower in DNFB-treated ears compared with vehicle
treatment (3.74 vs. 30.51%). Correspondingly, the percentage
of living cells (Annexin V-/7-AAD–) was higher in the DNFB-
treated sample than in the control (45.59 vs. 29.38%),
indicating that DNFB stimulation increased tumor cell
resistance to apoptosis in the transplanted environment
(Figure 3a, C). The expression of proliferating cell nuclear
antigen indicated that increased proliferation was observed in
DNFB-treated ears at day 7 but not day 2 (Figure 3b).
Neutrophils and macrophages form the major infiltrating
populations in DNFB-induced tumor microenvironment
We next examined the inflammatory cell infiltrate 2 days
after MBL2 cell inoculation and a single topical application of
DNFB
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Figure 2. DNFB promotes the formation of tumors in C57BL/6 mice.
(a) DNFB (or vehicle) was applied only once after MBL2 cell inoculation. Ears
were examined after 48 hours or 2 weeks later. Bar¼ 100mm. (b) Ear thickness
of mice following vehicle, DNFB, and 12-O-tetradecanoylphorbol-13-acetate
(TPA) treatment was measured 2 weeks after tumor inoculation. (c) Clobetasol
propionate cream (0.05%) treatment was given for 5 consecutive days, either
just following MBL2 cell inoculation or 10 days later. Mice were killed 2
weeks after tumor cell inoculation with measurement of ear thickness (graph)
and documentation of tumor histology by hematoxylin and eosin (H&E)
staining (Supplementary Figure S2 online).
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Figure 3. DNFB promotes MBL2 cell survival through the changes of apoptosis and proliferation. (a) DNFB or vehicle was topically applied to ears injected
with MBL2 cells that were labeled in vitro with CellTracker CMRA before ear skin inoculation (A). Single-cell suspensions were created from pooled ear
skins (n¼ 4 per group) at 48 hours for analysis by flow cytometry (B). Based on gating in B, percentages of apoptotic (Annexin Vþ /7-AAD–), dead (Annexin
Vþ /7-AADþ ), and live cells (Annexin V-/7-AAD–) in CMRA-labeled tumor cells are shown graphically (C). (b) Detection of proliferating cell nuclear antigen
(PCNA) by western blot at indicated time points from extracts from vehicle-treated (lanes 1 and 3) and DNFB-treated (lanes 2 and 4) MBL2 (lanes 1 and 2)
and MBL2-Luc (lanes 3 and 4) inoculated ears.
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DNFB on mouse ears. MBL2 cells were excluded from flow
cytometric analysis by labeling the cells with CMRA
CellTracker before ear injection. Total infiltrating CD45þ
leukocytes in whole ear cell suspensions increased from
13.1% (in vehicle-treated groups) to 20.1% (in DNFB-treated
groups; Figure 4a). Further analysis showed that Gr-1high
neutrophils and F4/80þ macrophages contributed 44.69 and
54.81%, respectively, to the total leukocytes in DNFB-treated
ears (Figure 4a). CD3þ T cells accounted for a small
percentage of the tumor infiltrate, whereas very few B cells
and natural killer cells were detected (data not shown). To
evaluate whether the minority cells, i.e., T, B, and natural
killer cells, influenced tumor promotion by DNFB, we
injected MBL2 cells into the ear skin of SCID/Beige mice,
which lacked functional T, B, and natural killer cells.
Although tumors formed in the ears of SCID/Beige mice
without DNFB stimulation, the ear tumors were substantially
thicker when DNFB was applied after tumor cell inoculation
(Figure 4b). Thus, DNFB is capable of enhancing tumor
growth in the absence of T, B, and natural killer cells.
Depletion of skin-localized macrophages with clodronate
blocks tumor promotion induced by DNFB
As the majority population in inflamed tumor environments
came from macrophages and neutrophils, we specifically
depleted these cells to define the cell types responsible for the
tumor-promoting effect in our model system. Neutrophils
were depleted by intraperitoneal injection of anti-Gr-1
antibody, and macrophages were depleted by intraear
injection of clodronate-containing liposomes (van Rooijen
and Hendrikx, 2010; Figure 5a). Neutrophil depletion did not
affect the F4/80þ cell population, nor did macrophage
depletion affect the Gr1þ cell population (Supplementary
Figure S8 online). Although neutrophil depletion did not
affect DNFB-induced tumor formation, depletion of macro-
phages largely abolished the effect of DNFB on tumor growth
(Figure 5b and Supplementary Figure S3 online). In order to
correlate this finding to human CTCLs, we examined
macrophage infiltration in biopsies from five cases of plaque-
and tumor-stage MF. By staining with mAb against the
macrophage marker, CD163 (Fuentes-Duculan et al., 2010),
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Figure 4. Inflammatory infiltrates in DNFB-induced tumor microenvironment are predominantly composed of neutrophils and macrophages. (a) Topical
0.5% DNFB (10 ml) or vehicle (10ml) was applied once over the injection site of C57BL/6 ear skin after CMRA-labeled MBL2 cell inoculation. After 2 days,
single-cell suspensions were stained for inflammatory markers and analyzed by flow cytometry. Infiltrating leukocytes were identified by CD45 exclusively
of CMRAþ tumor cells. Infiltrating leukocytes were analyzed for the expression of Gr-1 (neutrophil), F4/80 (macrophage), and CD3 (T lymphocytes).
(b) SCID/Beige mice were inoculated with MBL2 cells and treated with DNFB or vehicle (see Materials and Methods). Ear thickness (graph, n¼ 5) was used
to assess tumor growth shown in the graph. Histology of MBL2-inoculated SCID/Beige ears by hematoxylin and eosin (H&E) staining. Bar¼200 mm.
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abundant macrophages were observed intermingled among
tumor cells (Figure 5c) in all five specimens. In comparison,
CD163þ macrophages were much fewer in number in
healthy human skin (Supplementary Figure S6 online). Thus,
macrophages are critical for tumor development following
topical DNFB application in our model and appear to be
increased in number in human plaque- and tumor-stage MF
lesions.
DNFB alters the gene expression profile of inflammatory
cytokines and chemokines in tumor transplants
In order to identify specific changes in the molecular level of
DNFB-induced tumors, we performed array-based PCR
transcriptional profiling of a limited variety of inflammatory
cytokines, chemokines, and their respective receptors. RNA
was extracted from both DNFB- and vehicle-treated ears 2
days after MBL2 inoculation. Among a total of 168 genes
screened (Supplementary Table S1 online), 15 genes were
upregulated and another 15 were downregulated by43-fold
in DNFB-treated ears compared with vehicle control (Sup-
plementary Table S2 online). Regular quantitative reverse
transcriptase-PCR followed to confirm the changes of the
partial (Supplementary Figure S4 online). The over- or under-
expressed genes were classified into three categories. The
largest group consisted of upregulated chemokines, e.g.,
CCL6, CXCL1, CXCL2, CXCL5, and CXCL7 (pro-platelet basic
protein (PPBP)), produced mainly from myeloid lineages, and
their cognate receptors. Interestingly, the genes encoding
proteins that attracted T cells and were involved in adaptive
immunity were found to be downregulated in DNFB-inflamed
ears. We identified a third category of regulated genes that
have been clearly documented to affect tumor development
by regulating cell proliferation, angiogenesis, or apoptosis.
These data provide a profile of potential activators that link
inflammation and lymphoma tumor formation.
Enhanced activation of oncogenic signal pathways in the
inflammation-associated tumor milieu
NF-kB and signal transducer and activator of transcription 3
(STAT3) are key transcription factors that regulate the
production of proinflammatory cytokines and a variety of
target genes important for tumorigenesis. Thus, we examined
the expression levels and activation status of NF-kB and
STAT3 by western blot under the same conditions that were
used for cytokine analysis. Compared with vehicle treatment,
both phosphorylation of NF-kB p65, an event required for
maximal transcriptional activity of NF-kB, and phosphoryla-
tion of STAT3 were increased in DNFB-treated ear tumors
(Figure 6a). In addition, phospho-Akt was increased in
inoculated ears following DNFB treatment. To validate
mRNA array finding, we measured IL-1b protein expression
in the skin after topical DNFB treatment by western blot and
found it to be upregulated by at least 2-fold (Figure 6a). To
determine if IL-1b alone could simulate topical application of
DNFB, we co-injected IL-1b subcutaneously into flank skin
during implantation of MBL2 cells and observed significantly
increased tumorigenesis, although not to the same degree as
skin painting with DNFB (Figure 6b). The involvement of
these signaling pathways helped confirm the activities of
inflammatory regulators implicated in our PCR arrays.
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Figure 5. Depletion of macrophages, but not neutrophils, blocks the formation of tumors in DNFB-treated C57BL/6 mice. (a) Following neutrophil or
macrophage depletion (see Materials and Methods), MBL2-free mice were treated with DNFB (see Figure 2) and subsequently analyzed for effectiveness of the
depletions at day 3. Ear cell suspensions were analyzed with anti-Gr-1 and anti-F4/80 mAb. (b) Following 2 days of anti-Gr-1 or clodronate treatment,
mouse ears were inoculated with MBL2 cells and subsequently treated with DNFB. At week 2, tumors were assessed by ear thickness and histology
(Supplementary Figure S3 online). (c) Identification of macrophages with anti-CD163 staining in representative plaque-stage mycosis fungoides (MF; upper)
and tumor-stage MF (lower) biopsies (red: anti-CD3; green: anti-CD163; white dotted line marks epidermal basement membrane; bar¼ 100mm).
PBS, phosphate-buffered saline.
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DISCUSSION
Exploration of the underlying pathophysiology of MF and
other CTCLs has been limited by the lack of convenient
animal models for these diseases. Mice, except for one
isolated case report (Lohmiller et al., 1999), do not appear to
spontaneously develop CTCLs, rendering it nearly impossible
to establish bona fide murine CTCL or MF T-cell lines for
experimental research. Xenograft models of CTCLs in which
human CTCL skin has been grafted onto immunocompro-
mised mice (Charley et al., 1990) fail to take into account the
interactions (both positive and negative) of the host immune
system with lymphoma cells. Another xenograft CTCL model
that employs mice with a humanized immune system is
superior, but does not require an inflammatory stimulus to
drive tumor development (Yano et al., 2007).
Herein, we have generated a unique and convenient
transplanted murine lymphoma model for investigating the
complex interaction and balance between host antitumor
immunity and inflammation-mediated tumor promotion.
Topical DNFB treatment induced inflammation in the ear
skin of mice, promoted the survival of implanted MBL2 T
lymphoma cells, and eventuated in the development of
thick tumors in mouse ears. Depletion studies suggest a
central role of macrophages in our model and identify them
as a potential previously unreported cellular target for the
clinical treatment of CTCLs. Of note, increased numbers
of CD68þ (and CD163þ ) macrophages by immunohisto-
chemical staining has been recently associated with poor
prognosis in Hodgkin’s and follicular lymphomas (Clear
et al., 2010; Steidl et al., 2010).
Our results indicate that this model shares similarities with
some of the key clinical and pathological findings of human
MF, namely the presence of large atypical lymphocyte sheets
in the dermis, a mixture of inflammatory cells, including
macrophages, and activation of signaling pathways (i.e.,
IL-1b) that have been observed in human disease (Tron et al.,
1988). This model may also be useful as a preclinical model
to assess, to our knowledge, previously unreported inflam-
matory modulators that can be used to treat CTCLs. For
example, we showed that treatment with clobetasol propio-
nate clearly blocked tumor formation, but only if initiated
early during the inflammatory stage of tumor formation.
Interestingly, in early human patch and thin-plaque stage
CTCLs, potent topical corticosteroids such as clobetasol
propionate are considered first-line therapy, whereas they
are much less effective in tumor-stage disease (Zackheim
et al., 1998).
The major limitation of our model is that the MBL2 T
lymphoma line was not derived from a CTCL-like condition
in mice. As mentioned above, however, mice do not
spontaneously develop CTCLs or MF except in rare sporadic
cases (Lohmiller et al., 1999), and the few CTCL models
currently being used suffer from very important limitations in
interpretation. Importantly, the triggering of skin lymphoma
development by inflammatory cytokines and macrophages in
our model allows us to pose reasonable hypotheses about the
importance of these pathways and cells in human disease.
Our PCR array analysis identified genes important in
cellular proliferation (Lif) (Lobanok et al., 2008; Schraml
et al., 2008) and apoptosis (Gdf5 and cmtm5) (Shao et al.,
2007). Pathway analysis of the PCR array data using GNCpro
software (SA Bioscience, Frederick, MD) generated the gene
network, implicating the NF-kB and STAT3 pathways in our
DNFB-induced MBL2 tumors (Supplementary Figure S5
online). These findings were also experimentally verified
through the detection of enhanced phosphorylated NF-kB
p65 and STAT3 expression.
In conclusion, we present a, to our knowledge, previously
unreported model of inflammation-driven lymphoma pro-
gression in skin that bears some of the known features of
human plaque/tumor-stage MF. Revealing the molecular
basis underlying tumor development in this inflammation-
dependent model may give us further insights into human
CTCLs and suggest interventions that may be more clinically
effective than current therapies.
MATERIALS AND METHODS
Animals, human tissues, and cell lines
Female C57BL/6 mice and SCID/Beige mice (6–8 weeks old) were
purchased from the Jackson Laboratory (Bar Harbor, ME) and housed
at the Medical College of Wisconsin. All animal experiments were
conducted in accordance with the guidelines and approval of the
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Figure 6. DNFB treatment activates signal transducer and activator of
transcription 3 (STAT3), NF-jB, and IL-1b signaling pathways. (a) MBL2
(lanes 1 and 2) and MBL2-Luc (lanes 3 and 4) cells were inoculated into
C57BL/6 ear skin and treated with DNFB or vehicle. After 2 days, whole-ear
extracts were prepared for the detection of the indicated (phospho-) proteins
by western blot. Lanes 1 and 3, extracts from vehicle-treated, tumor
cell-inoculated ear skin; lanes 2 and 4, extracts from DNFB-treated, tumor
cell-inoculated ear skin. (b) Recombinant IL-1b (50 ng per mouse) was
co-injected with MBL2 cells subcutaneously (s.c.) in flank skin of mice. Tumor
growth was assessed 2 weeks after inoculation with MBL2 cells. Two control
groups included mice injected with MBL2 cells only and those treated with
topical DNFB after inoculation (2–6 mice per group).
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Institutional Animal Care and Usage Committee at the Medical
College of Wisconsin. Human tissues of MF and normal control were
collected from National Cancer Institute. The study was conducted
according to the Declaration of Helsinki Principles. The MBL2 cell
line (courtesy Dr Mark Udey, National Cancer Institute) was derived
from Moloney MuLV-induced T-cell lymphoma in C57BL/6 mice
(van Hall et al., 2000). The gag gene was deleted from the genome
of transformed MBL2 cells in order to lower virus-dependent
immunogenicity. MBL2 cells were cultured in Dulbecco’s modied
Eagle’s medium (Invitrogen) with 10% heat-inactivated fetal bovine
serum.
Retroviral transduction of MBL2 cells and luciferase assay
MBL2 cells were transduced with firefly (Photinus pyralis) luciferase
complementary DNA using a vector, pMSCVpuro (Clontech,
Mountain View, CA) and maintained with puromycin. This cell
line, named MBL2-Luc, did not show significant differences with
MBL2 parental cells in terms of proliferation rate or cell-cycle
kinetics. Expression of luciferase in MBL2 cells was used to quantify
tumor growth by luciferase assay (Promega, Fitchburg, WI) as
described (Murakami et al., 2002).
MBL2 tumor model in mouse ear skin
Phosphate-buffered saline-washed MBL2 cells (4 105 in 20ml
phosphate-buffered saline) were injected into the dermal space under
the central dorsal surface of the ears and above the cartilage plane
using a 30g needle. Tumor growth was assessed as either maximum
ear thickness using a digital caliper or total luciferase activity
(for MBL2-luc cells). Mice were topically treated with DNFB (0.5%
in a vehicle consisting of 4:1 (v/v) acetone and olive oil,
10ml per ear) (Fluka, Sigma-Aldrich, St Louis, MO) on dorsal ear
skins. Where indicated, DNFB, 12-O-tetradecanoylphorbol-13-acet-
ate (5mg per mouse in 10ml vehicle, Sigma, St Louis, MO), or vehicle
alone was topically applied over the injection site within 10minutes
of tumor cell inoculation. For inhibition of the DNFB-induced
inflammation, a highly potent topical corticosteroid, clobetasol
propionate cream (0.05%; Fougera) was applied on the ventral ear
skin daily for 5 days. On days 2 through 5, clobetasol cream was also
applied to the dorsal ear skin. In the late-phase treatment group,
clobetasol was applied daily on both dorsal and ventral skin from day
10 through day 14 on MBL2-inoculated DNFB-treated ears.
Preparation of single-cell suspension from mouse ear and flow
cytometry analysis
Mouse ears were amputated at the base with scissors. Each ear was
split into two pieces (dorsal and ventral) and incubated with Liberase
CI (Roche, Indianapolis, IN) for 45minutes at 37 1C. After digestion,
residual tissue was minced in complete RPMI containing 0.05%
DNase and disrupted using a Medimachine (BD Biosciences, San
Jose, CA). Released single cells were resuspended in FACS buffer for
apoptosis analysis with Annexin V and 7-aminoactinomycin D (7-
AAD; Apoptosis Detection Kit; BD Biosciences). For flow cytometry
analysis, cell suspensions were stained with indicated mAbs (BD
Biosciences) and anti-F4/80 mAb (eBioscience, San Diego, CA).
CellTracker probe labeling of MBL2 cells
MBL2 cells were centrifuged and re-suspended gently in prewarmed
serum-free medium solution containing CellTracker Orange CMRA
(Invitrogen) at 10 mM final concentration and then washed before
injection as per the manufacturer’s recommendations.
PCR array and quantitative real-time PCR
RT2 Profiler PCR Arrays (SA Bioscience) were used for cytokine/
chemokine receptor expression analysis. Briefly, 2 days after MBL2
tumor cell inoculation and DNFB or vehicle-treatment, single-cell
suspensions were pooled from inoculated ears (four mice per group).
Total RNA was extracted using the RNeasy kit (Qiagen, Valencia,
CA) and then converted into complementary DNA with the RT2 First
Strand Kit (SA Bioscience). Real-time PCR was performed on a
StepOne Plus Real-time PCR system (Applied Biosystem, Carlsbad,
CA). Regular quantitative real-time PCR was performed to confirm
PCR array results. Primer sequences are provided (Supplementary
Table S3 online).
Western blot
Whole ears were harvested and minced in RIPA buffer (Sigma)
containing a protease inhibitor cocktail (Complete-mini, EDTA-free
protease inhibitor cocktail; Roche Applied Science, Indianapolis,
IN). Following electrophoresis and transfer to nitrocellulose sheets,
antibodies to pan-Akt, phospho-Akt, pan-STAT3, phospho-STAT3,
phosphor-NFkB p65, proliferating cell nuclear antigen (Cell Signal-
ing Technology, Boston, MA), anti-b actin (Sigma), and anti-IL-1b
(Abcam, Cambridge, MA) were used for protein detection.
Immunofluorescence microscopy
Biopsy samples from skin lesions were fast-frozen; cut into 6mm
sections; fixed in cold acetone and blocked in 3% dry milk–pho-
sphate-buffered saline (Bio-Rad, Hercules, CA) and anti-CD16/32
mAb before 4 1C overnight incubation with primary antibodies,
anti-CD3 (eBioscience), and anti-CD163 (the macrophage marker,
Acris, San Diego, CA). Goat anti-mouse IgG1 Ab conjugated
with AlexaFluor 488 and Goat anti-mouse IgG2a conjugated with
AlexaFluor 568 (Invitrogen) were used for secondary detection.
Immunodepletion studies
For in vivo neutrophil depletion, 100 mg of anti-Gr-1 (RB6-8C5;
eBioscience) or rat IgG2a isotype control was injected intraperito-
neally for 2 consecutive days. Ears were inoculated with MBL2
cells and immediately treated with DNFB 4hours after the first
intraperitoneal injection of anti-Gr-1 or rat IgG2a. Macrophages
were depleted by subcutaneous injection of clodronate-containing
liposomes (gift of Roche Diagnostics, Indianapolis, IN) into mouse
ears (Shashkova et al., 2008). Ears were inoculated with MBL2 cells
and treated with DNFB at 1 day after twice-daily injection of 20 ml of
clodronate for 2 consecutive days.
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